CA
NZ
UK
AU
IND
US
Key HighlightsNNN REIT (NYSE:NNN) reported third-quarter netEarningsof USD 109.9 million, up from USD 96.8 million, after buying 76 properties at a 7.3% weighted average cap rate for USD 221.7 million.Global NetLease(NYSE:GNL) bookedImpairmentcharges of USD 58.2 million and a net loss of USD 56.9 million, …
Key HighlightsMacerich (NYSE:MAC) reported adjusted FFO of USD 0.37 per diluted share against USD 0.36, but two loans of USD 74.4 million and USD 325.0 million moved into default after quarter end.Tanger (NYSE:SKT) lifted 2026 FFO per share guidance to USD 2.49 to USD …
Key HighlightsThe Pennant Group (NASDAQ:PNTG) grew third-quarterRevenueto USD 302.3 million from USD 229.0 million, about 32% (calculated), whileNet Incomeattributable rose to USD 9.6 million, or USD 0.26 per diluted share.Option Care Health (NASDAQ:OPCH) lifted net revenue 4.1% to USD 1.49 billion and net income …
Key HighlightsMcKesson (NYSE:MCK) reported diluted EPS of USD 10.44 against USD 8.92, about 17% higher (calculated), on revenues up 8% to USD 110,957 million and diluted shares down to 116.7 million.STERIS (NYSE:STE) lifted adjusted EPS to USD 2.94 from USD 2.47 and raised its …
Key HighlightsEdgewise Therapeutics (NASDAQ:EWTX) reported third quarterNet Incomeof USD 1,166.2 million, or USD 9.65 per diluted share, driven by a gain of about USD 1,348.1 million on the sevasemten sale.Dianthus Therapeutics (NASDAQ:DNTH) posted a net loss of USD 46.6 million, or USD 0.81 per …
Key HighlightsRevolution Medicines (NASDAQ:RVMD) recorded USD 197.6 million of net productRevenuein the third quarter of 2026, its first from product sales, after FDA approval of RASONQUE in August.Relay Therapeutics (NASDAQ:RLAY) lost USD 81.7 million, or USD 0.37 per share, and holds USD 848.6 million …
Key HighlightsSummit Therapeutics (NASDAQ:SMMT) closed a USD 2.0 billion grossEquityInvestmentfrom AstraZeneca on October 5, 2026, with an FDA goal action date of November 14, 2026 for its ivonescimab BLA.Cytokinetics (NASDAQ:CYTK) reported USD 44.5 million of MYQORZO net productRevenueand narrowed its net loss to USD …
Key HighlightsNewAmsterdam Pharma (NASDAQ:NAMS) reported third-quarterRevenueof USD 19.2 million, versus USD 0.3 million a year earlier, with USD 18.3 million of it license revenue.Tenaya Therapeutics (NASDAQ:TNYA) posted a net loss of USD 18.9 million, or USD 0.08 per share, with cash and cash equivalents …
Key HighlightsEdwards Lifesciences (NYSE:EW) reported net sales of USD 1,715.5 million, up 10.5%, and booked an intangible and long-lived assetImpairmentof USD 220.2 million, mainly a write-off of an in-processResearch and Developmentasset.PROCEPT BioRobotics (NASDAQ:PRCT) grewRevenue18% to USD 98.3 million, but net loss widened to USD …
Key HighlightsBio-Rad Laboratories (NYSE:BIO) reported dilutedEarningsof USD 17.02 per share against a loss of USD 12.70, helped by a USD 588.2 million fair-value gain, while net sales rose only 0.5% to USD 656.4 million.PacBio (NASDAQ:PACB) reportedRevenueof USD 40.6 million and aGAAPloss of USD 0.12 …
Please wait processing your request...